Exelixis
Exelixis, Inc. is an American commercial-stage oncology biotechnology company discovering and commercializing small molecule targeted cancer therapies. The company focuses its operational activities on small molecule research, clinical trials, and oncology drug sales. Its flagship commercial formulation is cabozantinib, marketed under the trade names CABOMETYX and COMETRIQ for renal cell, hepatocellular, and thyroid carcinomas. Primary revenue drivers are commercial product sales of CABOMETYX in the United States alongside licensing royalties and development milestones from partners Ipsen and Takeda. Exelixis holds a market-leading position in targeted renal cell carcinoma therapeutics. The company is headquartered in Alameda, California, and its shares trade on the Nasdaq Global Select Market.
12 of the funds FundTelligence covers report a position in Exelixis.
- Legal name
- Exelixis Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 12
Funds holding Exelixis
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.54 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 1.11 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Flerfaktor — KLP · 0.57 % (full portfolio disclosed, June 2026)
- Nordea BetaPlus Enhanced Global Sustainable Small Cap — Nordea Funds · 0.4 % (full portfolio disclosed, September 2026)
- JPM Global Value Fund — JPM · 0.18 % (full portfolio disclosed, June 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.16 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.15 % (full portfolio disclosed, September 2026)
- Schroder ISF QEP Global Quality — Schroders · 0.12 % (full portfolio disclosed, June 2026)
Showing the 8 largest of 12 funds holding it.